Literature DB >> 24118653

Cystectomy and urinary diversion as management of treatment-refractory benign disease: the impact of preoperative urological conditions on perioperative outcomes.

Joshua A Cohn1, Michael C Large, Kyle A Richards, Gary D Steinberg, Gregory T Bales.   

Abstract

OBJECTIVES: To investigate perioperative outcomes associated with cystectomy and urinary diversion for treatment-refractory benign urological disease.
METHODS: A cohort of patients who underwent cystectomy for infection, fistula, bleeding, incontinence, neurogenic bladder or pain between January 2004 and June 2012 was established. Data included baseline demographics, indications for cystectomy and prior treatments, and complications at 30 and 90 days. Primary outcome measures were 30-day and 30 to 90-day complications.
RESULTS: The study group comprised eight males and 18 females. The mean age was 57.8 years (95% CI 50.8-64.7). A total of 19 patients (73%) had resolution of their underlying urological pathology at 90 days. A total of 19 patients (73%) experienced a complication in the first 30 days, of which nine (47%) were Clavien grade III or higher. The most common 30-day complications were urinary tract infection (n = 6, 23%) and wound infection (n = 6, 23%). A total of 44% (4/9) of patients with neurogenic bladder experienced a complication within the first 30 days of cystectomy compared with 100% (8/8) of patients with radiation-induced fistula (P = 0.03) and 78% (7/9) of non-neurogenic, non-radiation-induced fistula patients (P = 0.34).
CONCLUSIONS: Cystectomy with urinary diversion for benign disease might be successful, but is associated with a high rate of perioperative complications. Those with radiation-induced fistula are more likely to experience complications, whereas those with neurogenic bladder carry a lower risk. Patients should be counseled appropriately regarding expected postoperative outcomes.
© 2013 The Japanese Urological Association.

Entities:  

Keywords:  benign disease; complications; cystectomy; fistula; radiation; reconstruction

Mesh:

Year:  2013        PMID: 24118653     DOI: 10.1111/iju.12284

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Outcomes and Quality of Life Among Men After Anal Sphincter-Sparing Transperineal Rectourethral Fistula Repair.

Authors:  Lindsay A Hampson; Wade Muncey; Mika N Sinanan; Bryan B Voelzke
Journal:  Urology       Date:  2018-09-04       Impact factor: 2.649

2.  Efficacy and safety of alvimopan use in benign urinary tract reconstruction.

Authors:  Patrick Hensley; Margaret Higgins; Alison Rasper; Ali Ziada; Stephen Strup; Clyde Coleman; Kathryn Ruf; Shubham Gupta
Journal:  Int Urol Nephrol       Date:  2020-08-31       Impact factor: 2.370

3.  Perioperative complications of conduit urinary diversion with concomitant cystectomy for benign indications: A population-based analysis.

Authors:  Elizabeth Timbrook Brown; David Osborn; Stephen Mock; Shenghua Ni; Amy J Graves; Laurel Milam; Douglas Milam; Melissa R Kaufman; Roger R Dmochowski; W Stuart Reynolds
Journal:  Neurourol Urodyn       Date:  2016-09-21       Impact factor: 2.696

4.  Temporal Trends in Conduit Urinary Diversion With Concomitant Cystectomy for Benign Indications: A Population-based Analysis.

Authors:  Elizabeth Timbrook Brown; David Osborn; Stephen Mock; Shenghua Ni; Amy J Graves; Laurel Milam; Douglas Milam; Melissa R Kaufman; Roger R Dmochowski; W Stuart Reynolds
Journal:  Urology       Date:  2016-06-29       Impact factor: 2.649

5.  Neurogenic bladder: management of the severely impaired patient with complete urethral destruction: ileovesicostomy, suprapubic tube drainage or urinary diversion-is one treatment modality better than another?

Authors:  Douglas A Husmann; Boyd R Viers
Journal:  Transl Androl Urol       Date:  2020-02

6.  Pediatric cystectomy for refractory cystitis post-bone marrow transplant in dyskeratosis congenita: A case report.

Authors:  Eric Robinson; Casey Seideman; Trisha Wong; Melanie Hakar; J Christopher Austin
Journal:  Urol Case Rep       Date:  2022-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.